Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Hypoxia-up-regulated mitochondrial movement regulator does not contribute to the APP/PS1 double transgenic mouse model of Alzheimer's disease.

Zou Y, Li Y, Yu W, Du Y, Shi R, Zhang M, Duan J, Deng Y, Tu Q, Dai R, Lü Y.

Dement Geriatr Cogn Disord. 2013;36(3-4):137-45. doi: 10.1159/000351669. Epub 2013 Jul 27.

PMID:
23900018
2.

Mitochondrial Sirt3 Expression is Decreased in APP/PS1 Double Transgenic Mouse Model of Alzheimer's Disease.

Yang W, Zou Y, Zhang M, Zhao N, Tian Q, Gu M, Liu W, Shi R, Lü Y, Yu W.

Neurochem Res. 2015 Aug;40(8):1576-82. doi: 10.1007/s11064-015-1630-1. Epub 2015 Jun 5.

PMID:
26045440
3.

Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway.

Jaffar S, Counts SE, Ma SY, Dadko E, Gordon MN, Morgan D, Mufson EJ.

Exp Neurol. 2001 Aug;170(2):227-43.

PMID:
11476589
5.

Alteration of cortical EEG in mice carrying mutated human APP transgene.

Wang J, Ikonen S, Gurevicius K, van Groen T, Tanila H.

Brain Res. 2002 Jul 12;943(2):181-90.

PMID:
12101040
6.

Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease.

Pedrós I, Petrov D, Allgaier M, Sureda F, Barroso E, Beas-Zarate C, Auladell C, Pallàs M, Vázquez-Carrera M, Casadesús G, Folch J, Camins A.

Biochim Biophys Acta. 2014 Sep;1842(9):1556-66. doi: 10.1016/j.bbadis.2014.05.025. Epub 2014 Jun 2.

7.

Early temporal short-term memory deficits in double transgenic APP/PS1 mice.

Lagadec S, Rotureau L, Hémar A, Macrez N, Delcasso S, Jeantet Y, Cho YH.

Neurobiol Aging. 2012 Jan;33(1):203.e1-11. doi: 10.1016/j.neurobiolaging.2010.07.023. Epub 2010 Sep 2.

PMID:
20817351
8.

Long-term social isolation exacerbates the impairment of spatial working memory in APP/PS1 transgenic mice.

Huang HJ, Liang KC, Ke HC, Chang YY, Hsieh-Li HM.

Brain Res. 2011 Jan 31;1371:150-60. doi: 10.1016/j.brainres.2010.11.043. Epub 2010 Nov 26.

PMID:
21114967
9.
10.

A neuronal model of Alzheimer's disease: an insight into the mechanisms of oxidative stress-mediated mitochondrial injury.

Sompol P, Ittarat W, Tangpong J, Chen Y, Doubinskaia I, Batinic-Haberle I, Abdul HM, Butterfield DA, St Clair DK.

Neuroscience. 2008 Apr 22;153(1):120-30. doi: 10.1016/j.neuroscience.2008.01.044. Epub 2008 Feb 7.

11.

Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.

van Groen T, Kiliaan AJ, Kadish I.

Neurobiol Dis. 2006 Sep;23(3):653-62. Epub 2006 Jul 10.

PMID:
16829076
12.
13.

Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice.

Dewachter I, Reversé D, Caluwaerts N, Ris L, Kuipéri C, Van den Haute C, Spittaels K, Umans L, Serneels L, Thiry E, Moechars D, Mercken M, Godaux E, Van Leuven F.

J Neurosci. 2002 May 1;22(9):3445-53.

14.

Altered levels and distribution of IGF-II/M6P receptor and lysosomal enzymes in mutant APP and APP + PS1 transgenic mouse brains.

Amritraj A, Hawkes C, Phinney AL, Mount HT, Scott CD, Westaway D, Kar S.

Neurobiol Aging. 2009 Jan;30(1):54-70. Epub 2007 Jun 11.

PMID:
17561313
15.

Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes.

Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K.

Nat Med. 1998 Jan;4(1):97-100.

PMID:
9427614
16.

Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice.

Saura CA, Chen G, Malkani S, Choi SY, Takahashi RH, Zhang D, Gouras GK, Kirkwood A, Morris RG, Shen J.

J Neurosci. 2005 Jul 20;25(29):6755-64.

17.

Regional metabolic alteration of Alzheimer's disease in mouse brain expressing mutant human APP-PS1 by 1H HR-MAS.

Woo DC, Lee SH, Lee DW, Kim SY, Kim GY, Rhim HS, Choi CB, Kim HY, Lee CU, Choe BY.

Behav Brain Res. 2010 Jul 29;211(1):125-31. doi: 10.1016/j.bbr.2010.03.026. Epub 2010 Mar 20.

PMID:
20307581
18.

APP/PS1 transgenic mice treated with aluminum: an update of Alzheimer's disease model.

Zhang QL, Jia L, Jiao X, Guo WL, Ji JW, Yang HL, Niu Q.

Int J Immunopathol Pharmacol. 2012 Jan-Mar;25(1):49-58.

PMID:
22507317
19.

Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice.

Sadowski M, Pankiewicz J, Scholtzova H, Ji Y, Quartermain D, Jensen CH, Duff K, Nixon RA, Gruen RJ, Wisniewski T.

J Neuropathol Exp Neurol. 2004 May;63(5):418-28.

PMID:
15198121
20.

Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice.

Dewachter I, van Dorpe J, Spittaels K, Tesseur I, Van Den Haute C, Moechars D, Van Leuven F.

Exp Gerontol. 2000 Sep;35(6-7):831-41. Review.

PMID:
11053674

Supplemental Content

Support Center